Nebula Research & Development LLC Viridian Therapeutics, Inc.\De Transaction History
Nebula Research & Development LLC
- $1.08 Trillion
- Q1 2025
A detailed history of Nebula Research & Development LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Nebula Research & Development LLC holds 12,531 shares of VRDN stock, worth $216,535. This represents 0.02% of its overall portfolio holdings.
Number of Shares
12,531
Previous 17,132
26.86%
Holding current value
$216,535
Previous $328 Million
48.57%
% of portfolio
0.02%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
187Shares Held
79.7MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$93 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$82.5 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$81.2 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$78.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$67.1 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $689M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...